SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Edward W. Brooke — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientEdward W. Brooke
Date of birth1919-10-26
IdentifiersMRN HR-ML014-SYN-TD; SSN (made up) 000-14-5063
Document date2003-02-10
AuthorHoward Bellamy, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-week follow-up on tamoxifen; bone density results; medical oncology seen today. [S]

History of Present Illness

Mr. Brooke returns four weeks after his first visit. He has taken tamoxifen 20 mg every day for fifteen weeks and keeps the bottle by his toothbrush. He has mild hot flashes two or three times a week, mostly at night, which do not stop him sleeping. He has had no leg swelling or pain, chest pain, or breathlessness, and no change in vision. The mastectomy scars are comfortable and he has full movement of the right shoulder, with no arm swelling. He had his DXA scan this morning and saw Dr. Cho of medical oncology, who has taken over his tamoxifen and sent a germline genetic test today. He starts vitamin D today for the low level found at the first visit. He walks most days. [S]

ElementDetail
TamoxifenFifteen weeks; no missed doses
Side effectsMild night hot flashes; no clot symptoms or visual change
Surgical sitesComfortable; full right shoulder movement; no arm swelling
CoordinationMedical oncology seen today; germline test sent

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fatigue, weight loss, or night sweats
EndocrinePositiveMild hot flashes at night
CardiovascularNegativeNo chest pain or leg swelling or pain
RespiratoryNegativeNo cough or breathlessness
MusculoskeletalNegativeNo bone pain; full shoulder movement
PsychiatricNegativeMood good; PHQ-2 score 0

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Tamoxifen 20 mg oral tablet, one tablet by mouth once daily (adjuvant endocrine therapy, planned for at least five years)One tablet once dailyOral route2002-10-28activeS
Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2003-02-10activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2003-02-10Body height183cmS
2003-02-10Body weight81.8kgS
2003-02-10Body mass index (BMI) [Ratio]24.4kg/m2S
2003-02-10Systolic blood pressure130mm[Hg]S
2003-02-10Diastolic blood pressure74mm[Hg]S
2003-02-10Heart rate68/minS
2003-02-10Respiratory rate14/minS
2003-02-10Body temperature36.7CelS
2003-02-10Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2003-02-10DXA Femur [T-score] Bone density-1.2{T-score}-1.0 or higher is normal; -2.5 or lower is osteoporosisLowS
2003-02-10DXA Lumbar spine [T-score] Bone density-0.4{T-score}-1.0 or higher is normal; -2.5 or lower is osteoporosisNormalS
2003-02-10Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Physical Exam

Vital signs recorded on 2003-02-10; see the Vital Signs section. [S]

SystemFinding
GeneralWell
Chest wallHealed transverse mastectomy scars on both sides; no nodule or skin change
Lymph nodesRight axillary scar healed; no axillary, supraclavicular, or cervical nodes on either side
ExtremitiesUpper arm circumference 31 cm on both sides; no calf swelling or tenderness

Problems

ProblemClinical statusVerificationCodeProvenance
Invasive ductal carcinoma of the right male breast, central (retroareolar) portion, stage IIA (pT1c pN1a M0), grade 2, ER positive, PR positive, HER2 negative; treated by bilateral mastectomy and right axillary lymph node dissection; on adjuvant tamoxifen; synthetic modern detail linked to his publicly disclosed breast canceractiveconfirmed C50.121S — Synthetic tumor size, grade, receptor status, and stage; the diagnosis, the right side, the operation, and the spread to lymph nodes are from his public account (D).
Estrogen receptor-positive status of the breast canceractiveconfirmed Z17.0S — Synthetic receptor result; his tumor biology was not made public.
Long-term use of tamoxifen, with safety monitoring (venous thromboembolism, mood, hot flashes, sexual side effects, adherence) and bone health reviewactiveconfirmed Z79.810S — Synthetic adjuvant therapy in the modern episode.
Absence of both breasts after bilateral mastectomyactiveconfirmed Z90.13S — The double mastectomy is reported publicly (D); the coding is synthetic.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationCancer-related history and examination of both sides of the chest wall and both axillaeEvery 3 to 6 months for 3 yearsCompleted todayNo nodule, skin change, or nodes
ExaminationLymphedema assessment and risk-reduction counselingEvery visit after axillary surgeryCompleted todayArm circumferences equal at 31 cm; skin care and early reporting reviewed
Medication safetyVenous thromboembolism symptoms on tamoxifenEvery visit on tamoxifenCompleted todayNo leg swelling or pain, chest pain, or breathlessness
Medication safetyHot flashes on tamoxifenEvery visit on tamoxifenCompleted todayMild, at night; no treatment needed. Paroxetine, fluoxetine, and bupropion are to be avoided because they block the activation of tamoxifen
Medication safetySexual side effects of tamoxifen (libido, erectile function)Every visit on tamoxifenDeferredNot asked today, a deviation from the protocol; the visit was taken up by the bone density and consultation results. To be asked at the next visit
Medication safetyAdherence to tamoxifenEvery visit on tamoxifenCompleted todayNo missed doses; pill bottle kept by his toothbrush
SurveyDistress and depression screen (PHQ-2)Every visitCompleted todayPHQ-2 score 0
ImagingBone density (DXA)Baseline on hormone therapy, then every 2 yearsCompleted todayFemoral neck T-score -1.2 (low bone mass); lumbar spine -0.4 (normal)
Laboratory25-hydroxyvitamin DAt baseline, then three months after starting a supplementDue24 ng/mL at the first visit; recheck in three months
LaboratoryGermline multigene panel testingOnce, for every man with breast cancerOrderedBlood sent today by medical oncology; genetic counseling before and after the result
ReferralMedical oncologyOnce, then as the oncologist advisesCompleted todaySeen today; recommendations in the consultation note
ImagingBreast imaging (mammography)Yearly only for a remaining breast after lumpectomy, or the other breast with a predisposing variantNot indicatedBoth breasts were removed; there is no breast tissue to image
LaboratoryRoutine blood tests, tumor markers, and CT, bone scan, or PETNot recommended without symptoms in stage I to III diseaseNot indicatedNo symptoms suggesting recurrence
Self-managementPhysical activityEvery visitCompleted todayWalking most days; light weights added for bone health

Goal progress:

Guideline basis: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025); Shapiro CL, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)

Follow-up: Primary care review in three months with a vitamin D recheck. Genetic counseling appointment for the result. Medical oncology every six months. Next scheduled visit 2003-05-12: three-month follow-up: germline result, tamoxifen side effects and adherence, vitamin D recheck. [S]